Exact Sciences

FDA committee recommends approval of Exact Sciences’ Cologuard

Exact Sciences Corp. announced that the U.S. Food and Drug Administration’s (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee determined by a unanimous vote that Exact Sciences has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard ®, the company’s stool-based DNA (sDNA), non-invasive colorectal cancer screening test. Read more

Comments are closed.